Oligonucleotide Therapeutics – Nobel prize winning science comes of age
Craig Mellow and Andrew Fire won the Nobel prize for their discovery of RNA interference (RNAi) in 2006 and last year the first RNAi drug was approved in the USA (Patisiran, Alnylam) following on from other recent approvals in the space with anti-sense drugs including Nusinersen (Biogen/Ionis) on track to become the first block buster drug in this space. With at least 15 other oligonucleotide drugs in phase 3 or regulatory review for approval the oligonucleotide platform is now really becoming the 3rd arm of drug discovery alongside small molecules and antibodies. The challenges that have faced this platform, how they have been addressed to date and future developments will be discussed.
David Blakey has over 30 years of drug discovery and development experience and joined MiNA Therapeutics in 2015 as Chief Scientific Officer. He has been leading MiNA’s internal and external R&D efforts in the oligonucleotide space. Prior to joining MiNA Therapeutics, David was Chief Scientist in Oncology at AstraZeneca and led a team that developed AstraZeneca’s R&D strategy in oligonucleotides championing several strategic collaborations. David has a Biochemistry degree from Oxford and a PhD from London University.